AbCellera Biologics (ABCL) – Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of AbCellera Biologics (NASDAQ: ABCL) in the last few weeks:

• 1/21/2026 – AbCellera Biologics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – AbCellera Biologics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/12/2026 – AbCellera Biologics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/4/2026 – AbCellera Biologics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/27/2025 – AbCellera Biologics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.